| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 9.10 | -0.19 (-2.05%) | 4.00 - 12.70 | 278.6 thousand (Below Avg) |
Market data as of 3:59PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 9.38 |
|---|---|
| Previous Close | 9.29 |
| Day's Range | 9.02 - 9.50 |
| Market Cap | 255.2M |
| Avg Volume (10 Day) | 334.6K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.29 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Record Use of At-the-Market (ATM) Offerings Continues in 2013 with $161 Million Raised by U.S. Life Sciences Companies in First Quarter, Reports Brinson Patrick
PR Newswire - Tuesday 05/28/2013 8:00 AM ET
| CNDO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.53 | |
| LT Debt/Equity | 0.41 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Sunesis Pharmaceuticals Inc | 5.02 | +0.20% |
| OvaScience Inc | 13.93 | 0.00% |
| Vical Inc | 2.96 | +1.02% |
| Synta Pharmaceuticals Corp | 4.00 | +0.50% |
| Curis Inc | 3.44 | +0.58% |
Data is delayed by at least 15 min.